Hims, weight loss

Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Analysts Have Mixed Reviews on Hims & Hers Stock Amid Uncertainty Around Weight Loss Business
Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth for the
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel?
With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche-Zealand deal is the latest to boost obesity space
Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts weight loss drug stocks. Read more here.
‘Don’t Buy the Dip,’ Says Morgan Stanley About Hims & Hers Stock
Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Why Hims & Hers Health Stock Just Popped
Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Zacks.com on MSN3d
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...